Clinical trials: HER2 Expression
Breast Cancer
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.
- Trial name
- ABC (NCT00479674)
- Testing
- Abraxane, Bevacizumab, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Early-Stage Breast Cancer
Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer
This multi-center randomized Phase II study assigned HER2-negative early-stage breast cancer patients to receive preoperative systemic chemotherapy in either a "genomic-guided" arm or a "non-guided arm." The "genomic-guided"…
- Trial name
- NCT00636441
- Testing
- Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Duke University
Breast Cancer
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of trastuzumab emtansine (T-DM1) plus lapatinib (L)followed by abraxane (A) versus trastuzumab plus pertuzumab followed by paclitaxel…
- Trial name
- TEAL (NCT02073487)
- Testing
- T-DM1, Trastuzumab, Lapatinib
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer
Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
The majority pf breast cancers present as ER-positive, many of which are able to be targeted with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has the potential to benefit patients by making…
- Trial name
- NCT00726180
- Testing
- trastuzumab (Herceptin®)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
This study will evaluate the efficacy and safety of pertuzumab (rhuMAb 2C4) in participants with metastatic breast cancer which has progressed during or after standard chemotherapy and which is not amenable to curative therapy.
- Trial name
- NCT02491892
- Testing
- Pertuzumab
- Where
- 18 sites in Australia, Belgium and 6 more
- Volunteers
- 79 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
The purpose of the study is to compare the efficacy of treatment with afatinib plus letrozole to treatment with letrozole alone in women diagnosed with a specific type of breast cancer.
- Trial name
- NCT02115048
- Testing
- Letrozole, Afatinib
- Where
- 26 sites in United States, Bosnia and Herzegovina and 2 more
- Volunteers
- 44 people
- Sponsor
- Translational Research in Oncology
Breast Neoplasms, Breast Cancer
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Background: Human epidermal growth factor receptor 2 (HER2, also known as c-erbB2 or neu)/neu (HER2) is a tumor protein that appears in almost a third of breast cancers and in several other types of cancers such as colon…
- Conditions
- Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
- Trial name
- NCT01730118
- Testing
- Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
This randomized pilot clinical trial studied whether the Oncotype DX gene expression "Recurrence Score" (RS) would be useful for helping make a decision about which type of pre-operative treatment, hormone therapy or chemotherapy…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT01293032
- Testing
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Virginia Commonwealth University
Metastatic Breast Cancer
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.
- Trial name
- NCT01207102
- Testing
- Abraxane, Carboplatin
- Where
- 2 sites in United States, China
- Volunteers
- 10 people
- Sponsor
- Duke University
Breast Cancer, Non Small Cell Lung Cancer
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2).
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
- Trial name
- NCT03125200
- Testing
- ADCT-502
- Where
- 5 sites in United States, Belgium
- Volunteers
- 21 people
- Sponsor
- ADC Therapeutics S.A.
Breast Cancer Metastatic
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2.
- Trial name
- NCT03321981
- Testing
- Zenocutuzumab, Trastuzumab, Vinorelbine
- Where
- 25 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Merus B.V.
Non-Small Cell Lung Cancer
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.
- Trial name
- DESTINY-Lung01 (NCT03505710)
- Testing
- Trastuzumab deruxtecan
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 181 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
The purpose of this study is to find out if there is a benefit of adding Herceptin (trastuzumab) to standard chemotherapy in this type of breast cancer.
- Trial name
- NCT00944047
- Testing
- nab-paclitaxel, trastuzumab, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Kansas Medical Center